NCT04947254View on ClinicalTrials.gov

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 5, 2021

Primary Completion Date

June 7, 2026

Study Completion Date

June 7, 2026

Conditions
Prostate CarcinomaStage IIC Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IIIA Prostate Cancer AJCC v8Stage IIIB Prostate Cancer AJCC v8Stage IIIC Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8
Interventions
DRUG

Abiraterone Acetate

Given PO

DRUG

Antiandrogen Therapy

Given ADT

DRUG

Apalutamide

Given PO

PROCEDURE

Biopsy

Undergo biopsy

DRUG

Niraparib

Given PO

DRUG

Prednisone

Given PO

RADIATION

Radiation Therapy

Undergo radiation therapy

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER